Abstract | BACKGROUND: DESIGN AND METHODS: In this study, both ADAMTS13 antigen and activity levels were measured in 835 sequential samples from 40 consecutive patients who were followed for an average of 29 months throughout the course of acute episode plasma exchange treatment and clinical remission. RESULTS: During acute episodes, ADAMTS13 activity was severely deficient while ADAMTS13 antigen levels were more variable, ranging from severely deficient to as high as within the reference range. A severe depletion of ADAMTS13 antigen level during acute disease was, however, statistically associated with disease mortality (P=0.0322). For patients who achieved initial clinical responses, ADAMTS13 antigen levels appeared to be restored faster than ADAMTS13 activity to the normal range. Further analysis demonstrated that the ADAMTS13 antigen level at the time of initial clinical recovery was significantly higher in the patients who subsequently achieved a sustained clinical remission than in the group who soon after had an exacerbation (P=0.0187). CONCLUSIONS:
|
Authors | Shangbin Yang, Ming Jin, Shili Lin, Spero Cataland, Haifeng Wu |
Journal | Haematologica
(Haematologica)
Vol. 96
Issue 10
Pg. 1521-7
(Oct 2011)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 21606162
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Neutralizing
- ADAM Proteins
- ADAMTS13 Protein
- ADAMTS13 protein, human
|
Topics |
- ADAM Proteins
(immunology, metabolism)
- ADAMTS13 Protein
- Adolescent
- Adult
- Aged
- Antibodies, Neutralizing
(blood)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Plasma Exchange
- Purpura, Thrombotic Thrombocytopenic
(diagnosis, mortality, therapy)
- Treatment Outcome
- Young Adult
|